Nimesulide has
superior gastrointestinal safety as compared to other NSAIDs with
multi factorial approach for treating post-traumatic inflammation,
acute musculoskeletal disorders including sprains, strains,
tendinitis, tenosynovitis, low back pain, periarthritis (shoulder
pain) and osteoarthritis (joint pains), stiffness.
It
was launched in Italy for
the first time as Aulin and Mesulid in 1985 and is presently
available in more than 50 countries worldwide in different trademarks
Its
multifactorial mode of action gives it a unique and broad action on
inflammatory processes.
It
is available in the market in various like tablets
(100 mg), granules for oral suspension (100 mg), suppositories (200
mg) and gel (3%).
The Gel needed to
be applied is three to four times per day depending on the dimension
of the affected size and response. Medicalcare ought to be reviewed
after 4 weeks.
Trademarks
of NImesulide include of Sulide, Nimalox, Nimesil,
Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan e.t.c.
Nimulid Transgel
is indicated for post-traumatic inflammation, acute musculoskeletal
disorders including sprains, strains, tendinitis, tenosynovitis, low
back pain, periarthritis (shoulder pain) and osteoarthritis (joint
pains), stiffness.
